Search Results
Search this site
658 results found with an empty search
- Skye Bioscience and Redx Pharma agree combination to create Fibrx Therapeutics with $125 million financing
The transaction creates a Nasdaq-listed fibrosis-focused company led by Redx’s management, with financing expected to fund the Phase II development of lead Crohn’s disease candidate RXC008 and provide cash runway into 2029. Skye Bioscience and Redx Pharma have entered a definitive agreement to combine and create Fibrx Therapeutics, alongside approximately $125 million of committed financing from new and existing investors. The combined company will focus on Redx’s fibrosis pipeline, led by Phase II-ready RXC008 for fibrostenotic Crohn’s disease, with the financing expected to support operations into 2029 and topline Phase II data in the second half of 2028. Field Content Alert Type Deal Companies Skye Bioscience; Redx Pharma; Fibrx Therapeutics Deal Type Business combination with concurrent private financing Asset or Company Fibrx Therapeutics, incorporating Redx Pharma’s fibrosis pipeline led by RXC008 Therapy Area(s) Gastroenterology; Fibrotic diseases; Inflammatory bowel disease Technology or Modality Small-molecule ROCK inhibitors; fibrosis-targeted therapeutics Deal Value The transaction is accompanied by approximately $125 million in committed financing, rather than a $125 million acquisition price. This includes approximately $68 million in private financing, a $36 million Series A financing and a $22 million equity line involving Redmile and Skye; the announced financing arrangements are subject to their respective terms and conditions. (Fierce Biotech) Development Stage RXC008: Phase II-ready; DDR inhibitor programme: preclinical; zelasudil (RXC007): Phase II clinical data reported Geography United States and United Kingdom; development programmes have global potential What Happened On 14 August 2026, Skye Bioscience and privately held Redx Pharma announced a definitive agreement to combine and create Fibrx Therapeutics, a publicly traded biotechnology company focused on fibrotic diseases. The combined company will be led by Redx CEO Lisa Anson, headquartered at Redx’s existing Alderley Park site in the UK and is expected to trade on Nasdaq following completion. Pre-transaction Skye shareholders are expected to own approximately 5.38%, existing Redx investors approximately 46.17% and investors participating in the new financing approximately 48.45% of Fibrx. The transaction remains subject to shareholder approvals and other closing conditions. (Fierce Biotech) Why It Matters The combination provides Redx’s fibrosis programmes with access to the public markets and new capital to advance development, while giving Skye shareholders exposure to a substantially different clinical pipeline after Skye paused development of obesity candidate nimacimab. The immediate development priority is RXC008, a GI-restricted pan-ROCK inhibitor intended to target intestinal fibrosis in fibrostenotic Crohn’s disease, an area where existing therapies do not directly address the underlying fibrosis. (Fierce Biotech) Supporting Context RXC008 has completed Phase I development and received FDA Fast Track designation in January 2026. Beyond RXC008, Fibrx is expected to retain Redx’s preclinical DDR inhibitor programme targeting kidney, lung and liver fibrosis, while selective ROCK2 inhibitor zelasudil (RXC007) is available for partnering following Phase IIa development in idiopathic pulmonary fibrosis. (Fierce Biotech) Strategic Rationale Redx gains a route to the Nasdaq public markets and substantial financing for its fibrosis pipeline, while Skye effectively redirects its corporate platform towards Redx’s programmes following a strategic review of nimacimab. Existing Skye shareholders will retain an additional economic interest in nimacimab through entitlement to 90% of net cash proceeds realised from any future monetisation of the programme and associated intellectual property. (Fierce Biotech) Potential Impact The financing is expected to provide Fibrx with cash runway into 2029 and fund RXC008 through its planned Phase II trial in fibrostenotic Crohn’s disease. Successful development could establish proof of concept for directly targeting intestinal fibrosis, but this remains dependent on prospective Phase II results. (Fierce Biotech) Key Takeaway The Skye-Redx combination creates a newly financed public biotechnology company centred on Redx’s fibrosis pipeline, with RXC008 and its upcoming Phase II Crohn’s disease study as the principal near-term value driver. What to Watch Transaction closing and shareholder approvals, initiation of the RXC008 Phase II study, the planned second-half 2028 topline data, progress of the DDR inhibitor towards an IND/CTA submission in 2027 and any partnering agreement for zelasudil. (Fierce Biotech) Primary Source Skye Bioscience and Redx Pharma definitive transaction announcement, 14 August 2026 Relevant Date 14 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Aizen Therapeutics signs AI peptide collaboration worth up to $100 million per target
The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets. Aizen Therapeutics has entered a multi-program drug discovery collaboration with an undisclosed publicly traded San Diego biotechnology company, providing Aizen with several million dollars in initial revenue and up to $100 million in milestone payments for each nominated target. The partnership will use Aizen’s DaX foundation model to design oral peptide therapeutics for disease-relevant targets in immunology and neurology, providing an early commercial test of its AI-enabled non-canonical amino acid peptide platform. Field Content Alert Type Deal Companies Aizen Therapeutics; undisclosed publicly traded San Diego biotechnology company Deal Type Multi-program drug discovery collaboration Asset or Company Aizen Therapeutics’ DaX foundation model and oral peptide discovery platform Therapy Area(s) Immunology; Neurology Technology or Modality AI-designed oral peptides; non-canonical amino acid (ncAA) peptide therapeutics Deal Value Aizen will receive several million dollars in initial revenue, with the potential for up to $100 million in milestone payments for each nominated target. The number of targets and individual milestone structure have not been disclosed, meaning a total potential transaction value cannot currently be calculated. The $100 million per target is contingent and should not be treated as guaranteed consideration. (PR Newswire) Development Stage Discovery Geography United States What Happened On 15 August 2026, Aizen Therapeutics announced a multi-program collaboration with an unnamed publicly traded San Diego biotechnology company to design oral peptide therapeutics using its DaX foundation model. The programmes will address disease-relevant targets in immunology and neurology, with Aizen receiving several million dollars in initial revenue and becoming eligible for up to $100 million in milestones for each target nominated by its partner. The partner’s identity, number of initial targets, specific programmes and detailed milestone structure were not disclosed. (PR Newswire) Why It Matters The agreement provides external commercial validation for Aizen’s AI-enabled peptide discovery platform while funding work intended to demonstrate that DaX-designed molecules can progress beyond computational design towards viable drug candidates. Aizen is attempting to combine the target specificity associated with peptide therapeutics with properties that could support oral delivery, although the partnered programmes remain at the discovery stage and their ability to produce clinically viable oral medicines has not yet been established. (PR Newswire) Supporting Context Aizen was spun out of Caltech and describes DaX as a computational design platform trained on millions of annotated molecules and receptors. The company says the platform explores the chemical space of non-canonical amino acid peptides at ten times the scale of traditional ncAA discovery methods and is being used across both its proprietary pipeline and biopharmaceutical collaborations. (PR Newswire) Strategic Rationale Aizen gains upfront revenue and the opportunity to demonstrate its platform against externally selected, disease-relevant targets, while the undisclosed partner gains access to DaX for the design of oral peptide candidates in immunology and neurology. The milestone-per-target structure also provides a mechanism for the collaboration to expand if additional programmes are nominated. (PR Newswire) Potential Impact Successful generation of orally viable peptide candidates could provide further validation for Aizen’s approach and support expansion of the collaboration or additional platform partnerships. Any therapeutic impact remains dependent on candidate discovery, preclinical validation and subsequent clinical development. Key Takeaway The collaboration gives Aizen several million dollars in initial revenue and potentially up to $100 million per nominated target while putting its AI-designed oral peptide platform to an external drug-discovery test. What to Watch Nomination of additional targets, disclosure of the partner or individual programmes and whether DaX-designed candidates demonstrate sufficient pharmacological and oral-delivery properties to progress towards IND-enabling development. Primary Source https://www.prnewswire.com/news-releases/aizen-enters-into-collaboration-with-san-diego-biopharma-to-advance-oral-biologics-302848775.html Relevant Date 15 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- British Columbia General Practice Billings Reach C$667,142, 13% Above Manitoba
New physician payment data show general practitioners generated higher median gross billings in British Columbia than in Manitoba. General practitioners recorded median gross physician billings of C$667,142 in British Columbia, compared with C$592,586 in Manitoba, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a valuable benchmark for general practitioners comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that general practitioners recorded median gross fee-for-service billings of C$667,142 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The findings demonstrate that general practice continues to generate substantial fee-for-service billings, reflecting the specialty's central role in delivering comprehensive, community-based patient care. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$667,142 for general practitioners, compared with C$592,586 in Manitoba. The C$74,556 difference means median general practice billings were approximately 13% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement systems, patient demand and practice models differ, the findings illustrate how gross physician billings can vary between Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, medical equipment and other operating costs—will significantly reduce the amount ultimately retained by individual physicians. Why general practice billings are at this level General practice is characterised by high patient volumes and a broad scope of clinical activity across acute, chronic and preventive care. Although consultations generally attract lower individual fees than many procedural specialties, the volume and continuity of patient care can generate substantial overall billings. Routine consultations, preventive health assessments, chronic disease management, minor procedures, vaccinations and follow-up appointments all contribute to fee-for-service activity. A busy community practice can therefore generate consistently high levels of gross billings over the course of a year. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings typically cover the cost of operating a general practice, including: Clinical and administrative staff Practice premises Medical equipment Information technology and electronic medical record systems Medical consumables Professional indemnity and other overheads Consequently, a general practitioner's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and does not fully capture physicians working under salaried, capitation or other alternative payment arrangements. What this means for general practitioners For general practitioners benchmarking their practice or considering opportunities in different provinces, the findings provide a useful indication of how gross fee-for-service billings can vary across Canada. However, billing figures should be interpreted as a measure of practice revenue rather than personal earnings. Differences in patient panel size, consultation volumes, reimbursement schedules and operating costs all influence the amount physicians ultimately retain. As additional provincial payment disclosures become available, specialty-specific comparisons will provide a clearer picture of how general practice billings vary across Canada's healthcare systems. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- British Columbia Family Physician Billings Reach C$704,097, 71% Above Manitoba
New physician payment data show family physicians generated substantially higher median gross billings in British Columbia than in Manitoba. Family physicians recorded median gross physician billings of C$704,097 in British Columbia, compared with C$411,038 in Manitoba, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a valuable benchmark for family physicians comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that family physicians recorded median gross fee-for-service billings of C$704,097 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The findings highlight a substantial difference in median gross billings between the two provinces, reflecting variations in fee-for-service activity and provincial reimbursement systems. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$704,097 for family physicians, compared with C$411,038 in Manitoba. The C$293,059 difference means median family medicine billings were approximately 71% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement models, patient volumes and practice structures differ, the findings illustrate how gross physician billings can vary significantly across Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, medical equipment and other operating costs—will significantly reduce the amount ultimately retained by individual physicians. Why family medicine billings are at this level Family medicine is characterised by high patient volumes and broad continuity of care across all age groups. Although individual consultations may attract lower fees than many procedural specialties, the volume of patient encounters and the breadth of services provided can generate substantial gross billings. Preventive care, chronic disease management, acute consultations, minor procedures, immunisations and ongoing longitudinal care all contribute to fee-for-service activity. The balance between consultation volume and procedural work can influence overall billing levels. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings typically cover the cost of operating a family medicine practice, including: Clinical and administrative staff Practice premises Medical equipment Information technology and electronic medical record systems Medical consumables Professional indemnity and other overheads Consequently, a family physician's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and does not fully capture physicians working under salaried, capitation or other alternative payment arrangements. What this means for family physicians For family physicians benchmarking their practice or considering opportunities in different provinces, the findings provide a useful indication of how gross fee-for-service billings can vary across Canada. However, billing figures should be interpreted as a measure of practice revenue rather than personal earnings. Differences in patient panel size, payment models, reimbursement schedules and operating costs all influence the amount physicians ultimately retain. As additional provincial payment disclosures become available, specialty-specific comparisons will provide a clearer picture of how family medicine billings vary across Canada's healthcare systems. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- British Columbia Urologist Billings Reach C$759,827, 20% Above Manitoba
New physician payment data show urologists generated significantly higher median gross billings in British Columbia than in Manitoba. Urologists recorded median gross physician billings of C$759,827 in British Columbia, compared with C$631,108 in Manitoba, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a valuable benchmark for urologists comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that urologists recorded median gross fee-for-service billings of C$759,827 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The findings place urology among the highest-billing physician specialties in both provinces, reflecting the specialty's combination of surgical procedures, diagnostic investigations and outpatient care within Canada's fee-for-service healthcare system. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$759,827 for urologists, compared with C$631,108 in Manitoba. The C$128,719 difference means median urology billings were approximately 20% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement systems, patient volumes and practice models differ, the findings illustrate how gross physician billings can vary across Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, diagnostic equipment and other operating costs—will significantly reduce the amount ultimately retained by individual physicians. Why urology billings are at this level Urology combines specialist consultations with a broad range of diagnostic, endoscopic and surgical procedures, creating multiple billable activities throughout the patient pathway. Procedures such as cystoscopy, prostate biopsies, stone management, minimally invasive surgery, cancer treatment and ongoing management of urinary tract conditions contribute to fee-for-service activity. The combination of procedural work and longitudinal patient care can support consistently high levels of gross billings. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings typically cover the cost of operating a urology practice, including: Clinical and administrative staff Practice premises Procedure and surgical facilities Endoscopic and diagnostic equipment Consumables Professional indemnity and other overheads Consequently, a urologist's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and does not fully capture physicians working under salaried or alternative funding arrangements. What this means for urologists For urologists benchmarking their practice or evaluating opportunities in different provinces, the findings provide a useful indication of how gross fee-for-service billings can vary across Canada. However, billing figures should be interpreted as a measure of practice revenue rather than personal earnings. Differences in reimbursement schedules, procedural mix, patient complexity and operating costs all influence the amount physicians ultimately retain. As additional provincial payment disclosures become available, specialty-specific comparisons will help build a more comprehensive picture of how urology billings vary across Canada's healthcare systems. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- British Columbia ENT Specialist Billings Reach C$771,834, 31% Above Manitoba
New physician payment data show otolaryngologists generated substantially higher median gross billings in British Columbia than in Manitoba. Otolaryngologists (ENT specialists) recorded median gross physician billings of C$771,834 in British Columbia, compared with C$590,994 in Manitoba, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a valuable benchmark for ENT specialists comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that otolaryngologists recorded median gross fee-for-service billings of C$771,834 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The findings place otolaryngology among the highest-billing physician specialties in both provinces, reflecting the specialty's combination of surgical procedures, outpatient interventions and specialist consultations within Canada's fee-for-service healthcare system. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$771,834 for otolaryngologists, compared with C$590,994 in Manitoba. The C$180,840 difference means median ENT billings were approximately 31% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement systems, patient volumes and practice models differ, the findings illustrate how gross physician billings can vary across Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, clinical equipment and other operating costs—will significantly reduce the amount ultimately retained by individual physicians. Why ENT billings are at this level Otolaryngology combines specialist consultations with a broad range of diagnostic, outpatient and surgical procedures, creating multiple billable activities across the patient pathway. Endoscopic examinations, hearing and balance assessments, airway procedures, sinus surgery, head and neck operations and ongoing outpatient management all contribute to fee-for-service activity. The combination of procedural work and specialist consultations can support consistently high levels of gross billings. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings typically cover the cost of operating an ENT practice, including: Clinical and administrative staff Practice premises Procedure and surgical facilities Diagnostic and endoscopic equipment Consumables Professional indemnity and other overheads Consequently, an otolaryngologist's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and does not fully capture physicians working under salaried or alternative funding arrangements. What this means for ENT specialists For otolaryngologists benchmarking their practice or evaluating opportunities in different provinces, the findings provide a useful indication of how gross fee-for-service billings can vary across Canada. However, billing figures should be interpreted as a measure of practice revenue rather than personal earnings. Differences in reimbursement schedules, case mix, procedural activity and operating costs all influence the amount physicians ultimately retain. As additional provincial payment disclosures become available, specialty-specific comparisons will help build a more comprehensive picture of how ENT billings vary across Canada's healthcare systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- British Columbia Cardiologist Billings Reach C$945,459, 26% Above Manitoba
New analysis of physician payment data shows cardiologists generated substantially higher median gross billings in British Columbia than in Manitoba. Cardiologists recorded median gross physician billings of C$945,459 in British Columbia, compared with C$748,873 in Manitoba, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a valuable benchmark for cardiologists comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that cardiologists recorded median gross fee-for-service billings of C$945,459 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The findings place cardiology among the highest-billing physician specialties in both provinces, highlighting the specialty's strong reimbursement profile within Canada's fee-for-service healthcare system. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$945,459 for cardiologists, compared with C$748,873 in Manitoba. The C$196,586 difference means median cardiology billings were approximately 26% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement systems, patient volumes and practice models differ, the findings illustrate how gross physician billings can vary across Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, diagnostic equipment and other operating costs—will significantly reduce the amount ultimately retained by individual physicians. Why cardiology billings are at this level Cardiology combines specialist consultations with a high volume of diagnostic and procedural activity, creating multiple billable services within a typical clinical pathway. Electrocardiography, echocardiography, stress testing, ambulatory cardiac monitoring, cardiac catheterisation and follow-up consultations all contribute to fee-for-service activity. In many practices, the combination of diagnostic investigations and ongoing management of chronic cardiovascular disease supports consistently high levels of gross billings. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings typically cover the cost of operating a cardiology practice, including: Clinical and administrative staff Practice premises Diagnostic equipment Cardiac imaging and monitoring infrastructure Consumables Professional indemnity and other overheads Consequently, a cardiologist's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and does not fully capture physicians working under salaried or alternative funding arrangements. What this means for cardiologists For cardiologists benchmarking their practice or evaluating opportunities in different provinces, the findings provide a useful indication of how gross fee-for-service billings can vary across Canada. However, billing figures should be interpreted as a measure of practice revenue rather than personal earnings. Differences in reimbursement schedules, patient case mix, procedural activity and operating costs all influence the amount physicians ultimately retain. As additional provincial payment disclosures become available, specialty-specific comparisons will help build a more comprehensive picture of how cardiology billings vary across Canada's healthcare systems. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Manitoba Gastroenterologist Billings Reach C$856,201, 11% Above British Columbia
New physician payment data show gastroenterologists generated higher median gross billings in Manitoba than in British Columbia. Gastroenterologists recorded median gross physician billings of C$856,201 in Manitoba, compared with C$774,242 in British Columbia, according to a new analysis of Canadian physician payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, they provide a useful benchmark for gastroenterologists comparing practice revenue across provincial healthcare systems. Key findings A new analysis of public physician payment disclosures found that gastroenterologists recorded median gross fee-for-service billings of C$774,242 per physician in British Columbia. The analysis uses official physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25) to compare physician billings by specialty. The Manitoba median was higher at C$856,201, showing a meaningful provincial difference in gross gastroenterology billings. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$774,242 for gastroenterologists, compared with C$856,201 in Manitoba. The C$81,959 difference means median gastroenterology billings were approximately 10.6% higher in Manitoba than in British Columbia. Provincial fee schedules, reimbursement systems, patient volumes, procedural activity and practice models may all contribute to the difference. These figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Why gastroenterology billings are at this level Gastroenterology combines specialist consultations with substantial diagnostic and procedural activity, creating multiple billable services across the patient pathway. Endoscopy, colonoscopy, gastroscopy, diagnostic testing, follow-up consultations and ongoing management of chronic gastrointestinal conditions can all contribute to fee-for-service activity. The specialty's procedural workload and relatively high patient throughput may therefore support elevated gross billings. Gross billings are not take-home pay The figures reported represent gross physician billings, not physician salaries or personal income. These billings may need to cover costs including: Clinical and administrative staff Practice premises Endoscopy and procedure facilities Diagnostic equipment Consumables Professional indemnity and other overheads Consequently, a gastroenterologist's net income will be substantially lower than the published billing figures. The analysis also primarily reflects fee-for-service payments and may not fully capture physicians working under salaried or alternative-payment arrangements. What this means for gastroenterologists For gastroenterologists benchmarking their practice or considering opportunities in different provinces, the findings show that gross fee-for-service billings can vary materially across Canada. The higher median in Manitoba may be relevant when comparing practice economics, but it should not be interpreted as evidence that gastroenterologists personally earn more there. Differences in reimbursement schedules, procedural mix, operating costs and practice structure will all influence the amount physicians ultimately retain. As additional provincial payment data become available, specialty-specific comparisons will provide a clearer picture of how gastroenterology billings vary across Canada. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Canadian Ophthalmologists Top C$1.18 Million in Gross Billings, Provincial Analysis Finds
New analysis of physician payment data places ophthalmology among Canada's highest-billing specialties, with median gross billings reaching C$1.18 million in British Columbia. Ophthalmologists recorded the highest median gross physician billings in British Columbia, reaching C$1.18 million, according to a new analysis of Canadian payment disclosures. While the figures represent gross fee-for-service billings rather than take-home income, the data reinforce ophthalmology's position as one of Canada's highest-billing medical specialties. Key findings A new analysis of public physician payment disclosures found that ophthalmology had the highest median gross fee-for-service billings in British Columbia, at C$1,187,999 per physician in 2024. The analysis draws on official payment data from British Columbia and Manitoba to compare physician billings by specialty. The report also found that ophthalmology consistently ranks among the highest-billing specialties across both provinces, highlighting the specialty's strong reimbursement profile within Canada's fee-for-service healthcare system. British Columbia versus Manitoba British Columbia recorded median gross physician billings of C$1,187,999 for ophthalmologists, compared with C$764,171 in Manitoba, according to the latest Open Compensation analysis of provincial physician payment disclosures. The C$423,828 difference means median ophthalmology billings were approximately 55% higher in British Columbia than in Manitoba. While provincial fee schedules, reimbursement models and clinical activity vary, the findings illustrate how physician billings can differ significantly across Canadian healthcare systems. It is important to note that these figures represent gross fee-for-service billings before practice overhead, rather than physician salary or take-home income. Practice expenses—including staffing, premises, equipment and other operating costs—will substantially reduce net earnings, meaning the published billings should be viewed as a measure of practice revenue rather than personal compensation. Why ophthalmology ranks so highly Ophthalmology combines high patient volumes with a large number of reimbursable diagnostic and surgical procedures. Routine cataract surgery, intravitreal injections, laser treatments, retinal procedures and advanced imaging all contribute to significant fee-for-service activity. Unlike consultation-heavy specialties, ophthalmologists can often complete multiple billable procedures within a single clinical session, increasing total annual billings. Gross billings are not take-home pay It is important to note that the figures reported are gross physician billings, not physician salaries or personal income. These billings must cover the cost of running a practice, including: Clinical and administrative staff Practice premises Surgical facilities Diagnostic equipment Consumables Professional indemnity and other overheads Consequently, an ophthalmologist's net income will be substantially lower than the published billing figures. The analysis also focuses primarily on fee-for-service payments and does not fully reflect physicians working under salaried or alternative funding arrangements. What this means for ophthalmologists For ophthalmologists benchmarking their practice or considering opportunities in different provinces, the findings reinforce the specialty's position as one of Canada's highest-grossing fee-for-service disciplines. However, billing figures should be viewed as an indicator of practice revenue rather than personal earnings. Differences in operating costs, case mix, reimbursement schedules and practice structure all influence how much physicians ultimately retain. As additional provincial payment data become available, specialty-specific comparisons will provide a clearer picture of how ophthalmology compensation varies across Canada. Source Open Compensation. Which Medical Specialty Pays the Most in Canada? Physician Billings Ranked. Published 12 July 2026. The analysis uses physician payment disclosures from the British Columbia Medical Services Plan Blue Book (2024) and Manitoba Health (2024/25). Figures represent gross fee-for-service billings before overhead and should not be interpreted as physician salary or net income. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA clears Wandercraft’s Eve self-balancing exoskeleton for personal use in adults with spinal cord injury
The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion. The US Food and Drug Administration (FDA) has cleared Wandercraft’s Eve personal exoskeleton for eligible adults with spinal cord injuries at any level who can operate the device’s remote, enabling hands-free walking and activities of daily living on specified level surfaces under the supervision of a trained companion. The clearance creates a personal-use pathway for Wandercraft’s self-balancing technology outside rehabilitation institutions, with a US commercial launch planned for 17 September 2026. Field Content Alert Type Drug Approval Drug Name Eve personal exoskeleton Indication Personal-use powered exoskeleton for eligible adults with spinal cord injuries at any level who can operate Eve’s remote, supporting walking and activities of daily living on level indoor surfaces and immediately adjacent level outdoor areas under the supervision of a specially trained companion. (MassDevice) Therapy Area(s) Neurology; Spinal cord injury; Rehabilitation and mobility Geography United States (FDA) What Happened Wandercraft announced FDA clearance of Eve, its personal self-balancing exoskeleton, on 12 August 2026. Eligible adults with spinal cord injuries at any level who can operate the remote can use the device to walk and perform activities of daily living hands-free on specified level surfaces under supervision of a trained companion. Before use, patients require assessment by a licensed healthcare practitioner, individual device fitting and training alongside their companion. Unlike Wandercraft’s Atalante X, which is designed for use in rehabilitation institutions, Eve provides a pathway for personal use outside the rehabilitation setting. (MassDevice) Why It Matters Existing FDA-cleared personal exoskeletons such as ReWalk and Indego rely on crutches for balance and propulsion, while Eve uses self-balancing technology to enable hands-free upright mobility. For eligible people with spinal cord injuries, the clearance therefore introduces a different personal mobility option designed around standing, walking and performing everyday activities without requiring crutches for balance, although use still requires a trained companion and is restricted to specified surfaces. (MassDevice) Supporting Context FDA clearance was supported by a three-site clinical study involving people with spinal cord injuries and their companions. Participants underwent structured training followed by functional, usability and task-based assessments, with the programme evaluating whether users and companions could learn to operate Eve and complete activities relevant to personal use. (MassDevice) Key Takeaway FDA clearance moves Wandercraft’s self-balancing exoskeleton technology from rehabilitation-centre use towards personal mobility for eligible adults living with spinal cord injury. What to Watch Wandercraft plans to launch Eve commercially in the US on 17 September 2026 and anticipates potential Medicare reimbursement eligibility within 60–90 days; reimbursement is not yet confirmed. The company has also established evaluation, training and distribution partnerships ahead of launch. (MassDevice) Primary Source Wandercraft FDA clearance announcement; US Food and Drug Administration Relevant Date 12 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Sentynl secures option for US alvelestat rights in Phase III-ready AATD lung disease programme
The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development. Zydus Lifesciences subsidiary Sentynl Therapeutics has entered an option and licence agreement with Mereo BioPharma covering US commercial and global manufacturing rights to alvelestat, a Phase III-ready oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo will receive an undisclosed non-refundable option fee and, if Sentynl exercises its option, up to $40 million in upfront and R&D payments through NDA filing, with Mereo also eligible for tiered double-digit royalties on US net sales if the drug is approved. Field Content Alert Type Deal Companies Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences; Mereo BioPharma Deal Type Option and licensing agreement Asset or Company Alvelestat (MPH-966) Therapy Area(s) Respiratory; Rare disease; Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) Technology or Modality Oral small-molecule neutrophil elastase inhibitor Deal Value Mereo will receive an undisclosed non-refundable option fee. If Sentynl exercises the option, Mereo is eligible for up to $40 million in upfront and R&D payments through NDA filing, plus tiered double-digit royalties on US net sales if alvelestat is approved. The $40 million is contingent on option exercise and subsequent development and should not be treated as guaranteed consideration. (Economic Times Pharma) Development Stage Phase III-ready Geography United States commercial rights; global manufacturing rights What Happened Sentynl Therapeutics has entered an option and licence agreement with Mereo BioPharma for alvelestat. The agreement gives Sentynl an option to acquire exclusive US commercial rights and global manufacturing rights, while Mereo will lead the global Phase III study and regulatory interactions through completion during the option period. The companies will collaborate on manufacturing and refinement of the Phase III design, with Sentynl expected to sponsor the late-stage programme if it exercises the option. Mereo has previously indicated that a pivotal study could enrol approximately 220 patients over an 18-month treatment period. (Economic Times Pharma) Why It Matters The agreement provides Mereo with a potential route to finance and advance alvelestat into pivotal development while giving Sentynl access to a late-stage rare respiratory disease programme without immediately committing to a full licence. Alvelestat targets neutrophil elastase in AATD-LD, and Mereo has already aligned with the FDA and EMA on independent primary endpoints intended to support potential US and European regulatory submissions. (Mereo BioPharma) Supporting Context AATD-LD is a rare genetic condition caused by alpha-1 antitrypsin deficiency that can lead to progressive lung damage. Alvelestat has received FDA Orphan Drug and Fast Track designations and European orphan designation; Mereo has evaluated the drug across two Phase II studies and completed feasibility work in preparation for pivotal development. (Mereo BioPharma) Strategic Rationale Sentynl gains the option to add a Phase III-ready rare respiratory asset to its portfolio together with global manufacturing rights, while limiting its initial commitment during further development planning. Mereo gains a potential development and commercial partner while retaining responsibility for advancing the global Phase III programme during the option period. Potential Impact If the option is exercised and Phase III development is successful, the partnership could advance alvelestat towards regulatory submissions in AATD-LD and give Sentynl exclusive US commercial rights. Any clinical or commercial impact remains dependent on successful pivotal development and regulatory approval. Key Takeaway The option structure gives Sentynl access to a Phase III-ready rare respiratory programme while providing Mereo with a potential partner to advance alvelestat towards pivotal development and US commercialisation. What to Watch Exercise of Sentynl’s option, finalisation of the Phase III design and initiation of the pivotal programme, which Sentynl expects could begin in early 2027 if the option is exercised. (Economic Times Pharma) Primary Source Mereo BioPharma / Zydus Lifesciences-Sentynl Therapeutics agreement announcement Relevant Date 12 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Drugmakers curb Swiss reimbursement submissions amid US international drug-pricing concerns
Interpharma says seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for Swiss reimbursement, as companies consider the potential implications of Swiss prices for the US market. A survey by Swiss pharmaceutical industry association Interpharma found that seven of 22 new innovative medicines introduced between January 2025 and June 2026 were not submitted for inclusion on Switzerland’s reimbursement list, compared with an average of 24 submissions during equivalent 18-month periods between 2019 and 2025. Interpharma attributes the reduction partly to concerns that lower Swiss prices could influence US pricing under international benchmarking policies, creating a potential tension between pharmaceutical pricing strategy and timely Swiss patient access. Field Content Alert Type Industry Update Topic Pricing; reimbursement; market access Organisation(s) Interpharma; Swiss Federal Office of Public Health (FOPH) Affected Stakeholders Pharmaceutical companies launching innovative medicines in Switzerland; Swiss patients; payers and market-access teams Geography Switzerland; United States What Happened Interpharma reported on 13 August 2026 that seven of 22 new innovative medicines introduced between January 2025 and June 2026 were not submitted for Switzerland’s reimbursement list, which determines coverage under mandatory health insurance and establishes reimbursed prices. A further three medicines were not submitted for Swiss marketing approval. Interpharma linked the pattern to pharmaceutical companies’ concerns over the potential effect of Swiss pricing on US prices under the US administration’s most-favoured-nation pricing approach. The 15 medicines submitted for reimbursement compare with an average of 24 during equivalent 18-month periods between 2019 and 2025. (Global Banking & Finance Review) Why It Matters Inclusion on Switzerland’s Specialities List is important for broad access through mandatory health insurance. If manufacturers delay or avoid reimbursement applications because of the potential consequences of Swiss prices for larger markets such as the US, international reference-pricing policies could indirectly affect launch sequencing and patient access outside the country implementing the policy. The reported figures are based on an industry survey, however, and do not establish that US policy was the sole cause of every individual decision. (Global Banking & Finance Review) Supporting Context Switzerland’s FOPH assesses medicines for inclusion on the Specialities List and sets reimbursed prices. Swiss price-setting itself uses both an internal comparison with medicines for the same indication and an external comparison drawing on prices in nine European countries. (Federal Office of Public Health) Who Is Most Affected Pharmaceutical market-access and pricing teams face the most direct strategic issue because decisions on Swiss reimbursement may now need to consider potential international pricing consequences. Swiss patients are also directly affected where medicines are approved but not submitted for reimbursement, because routine access through mandatory health insurance may be unavailable, although reimbursement can be possible in qualifying individual cases. (Global Banking & Finance Review) Industry Impact The findings suggest international price referencing can influence not only medicine prices but also the order and timing in which manufacturers seek reimbursement across countries. If the pattern persists, smaller European markets used as international pricing benchmarks could face greater launch and reimbursement delays as manufacturers seek to manage the potential effect on prices in commercially larger markets. Key Takeaway Interpharma’s findings suggest US international drug-pricing policy is becoming a consideration in Swiss launch and reimbursement decisions, with potential consequences for patient access and pharmaceutical market-access strategy. What to Watch Whether reimbursement submissions remain below historical levels, how manufacturers sequence future Swiss and US launches, and whether Switzerland or the US modifies pricing policies in response to concerns about their effects on medicine availability. Primary Source Interpharma survey, reported 13 August 2026 Relevant Date 13 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com



